Shionogi

Roche agrees $1.4bn takeover of fibrosis specialist Promedior

At the moment, the only approved therapies for IPF are Roche/Shionogi’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib), which are both blockbuster drugs with sales in excess of

Shionogi scores FDA approval for new cUTI antibiotic

Pivotal new treatment for adults with complicated urinary tract infection. Japanese pharma Shionogi has won FDA approval for its antimicrobial drug Fetroja, in the treatment of adult patients with complicated urinary ... resistance mechanisms that

Roche scores another FDA approval for Xofluza

The drug was initially discovered and developed by Shionogi, and is being developed and commercialised globally in collaboration with Roche Group. ... Roche holds worldwide rights to the drug, excluding Japan and Taiwan, which are retained exclusively by

Roche’s flu drug Xofluza scores phase 3 primary endpoint

The drug was discovered and developed by Shionogi, and is already approved in Japan, with Roche holding the marketing rights outside Japan and Taiwan.

ViiV bags EU okay for new two-drug HIV therapy

ViiV – a joint venture majority owned by GlaxoSmithKline with Pfizer and Shionogi as shareholders – is relying on two-drug regimens to build market share in HIV, working on the premise that

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]